Journal
CLINICAL INFECTIOUS DISEASES
Volume 76, Issue -, Pages S163-S165Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciad093
Keywords
antimicrobial resistance; carbapenem-resistant Acinetobacter baumannii; sulbactam-durlobactam
Categories
Ask authors/readers for more resources
Antimicrobial resistance in gram-negative pathogens, especially Acinetobacter baumannii, poses a significant threat to human health. Sulbactam-durlobactam, a novel combination of beta-lactam and beta-lactamase inhibitor, is a promising agent against carbapenem-resistant A. baumannii. This article provides an overview of the development of SUL-DUR, highlighting its unique features and role in treating infections caused by CRAB pathogens.
Antimicrobial resistance in gram-negative pathogens, such as Acinetobacter baumannii, is a serious threat to human health. Sulbactam-durlobactam, a unique beta-lactam and a beta-lactamase inhibitor combination, is a novel agent targeted against carbapenem-resistant A. baumannii. This supplement provides a summary of the development of SUL-DUR, discussing its unique features and role in treating infections caused by CRAB pathogens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available